Clinical Characteristics and Prognosis of Secondary Acute Lymphoblastic Leukemia in Patients with Multiple Myeloma during Long-Term Thalidomide Maintenance
Open Access
- 25 February 2023
- journal article
- research article
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 13 (3) , 412
Abstract
Background: Secondary primary malignancies (SPM) have attracted increasing attention with the application of autologous hematopoietic stem cell transplantation (ASCT) and novel agents in multiple myeloma (MM). Secondary acute lymphoblastic leukemia (sALL) has rarely been reported, and the clinical characteristics and prognosis of sALL have not been described in detail. Methods: We retrospectively enrolled 179 consecutive newly diagnosed multiple myeloma (NDMM) patients undergoing bortezomib-based induction regimens followed by upfront ASCT and maintenance therapy from December 2006 to April 2018 in our center. Results: The median follow-up interval was 69.1 months, and 12 patients (6.7%) developed sALL during maintenance therapy. The median time from the diagnosis of MM to the occurrence of sALL was 51.1 (31.7–91.5) months. All sALL patients received thalidomide as maintenance therapy before the onset of sALL, and the median duration of thalidomide maintenance was 39.5 (24–74) months. The cumulative incidence of sALL was 6.6% and 11.2% at 5 and 10 years after the diagnosis of MM, respectively. All sALL patients presented with a B-cell immunophenotype accompanied by myeloid antigen expression according to flow cytometry analysis, and the BCR/ABL fusion gene was all negative. Only one patient had evidence of active MM, and the other patients were in stable status at the time of the diagnosis of sALL. The prognosis of most sALL patients was very poor, and the median overall survival time was 11.9 (1.1–51.2) months since the diagnosis of sALL. Conclusions: sALL should be considered for MM patients who developed unexplained persistent cytopenia while on long-term thalidomide maintenance treatment, particularly if it has been more than 3 years. With the increasing availability of new drugs for MM, thalidomide may be recommended for no more than 3 years. Sequential allogeneic hematopoietic stem cell transplantation was considered as soon as possible after achieving remission in order to achieve a longer survival.Keywords
Funding Information
- Natural Science Foundation of Guangdong Province (2018A030313651)
This publication has 29 references indexed in Scilit:
- Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenanceBlood, 2012
- Continuous Lenalidomide Treatment for Newly Diagnosed Multiple MyelomaNew England Journal of Medicine, 2012
- Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple MyelomaNew England Journal of Medicine, 2012
- Lenalidomide after Stem-Cell Transplantation for Multiple MyelomaNew England Journal of Medicine, 2012
- A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomideBlood, 2012
- Secondary acute lymphoblastic leukaemia in a multiple myeloma patientContemporary Oncology, 2012
- Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS)Blood, 2011
- Biologic features and treatment outcome of secondary acute lymphoblastic leukemia—a review of 101 casesAnnals of Oncology, 2008
- Acute lymphoblastic leukemia after tandem autologous stem cell transplantations for multiple myelomaLeukemia, 2004
- The Chemotherapy of Plasma-Cell Myeloma and the Incidence of Acute LeukemiaNew England Journal of Medicine, 1979